Cargando…

Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer

The risk factors for predicting bone metastases in patients with breast cancer are still controversial. Here, a total of 2133 patients with breast cancer, including 327 with bone metastases (15.33%) and 1806 without bone metastases (84.67%) were retrospective reviewed from January 2005 to December 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wen-Zhao, Shen, Jun-Feng, Zhou, Yang, Chen, Xuan-Yin, Liu, Jia-Ming, Liu, Zhi-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595860/
https://www.ncbi.nlm.nih.gov/pubmed/28900285
http://dx.doi.org/10.1038/s41598-017-11700-4
_version_ 1783263433611804672
author Chen, Wen-Zhao
Shen, Jun-Feng
Zhou, Yang
Chen, Xuan-Yin
Liu, Jia-Ming
Liu, Zhi-Li
author_facet Chen, Wen-Zhao
Shen, Jun-Feng
Zhou, Yang
Chen, Xuan-Yin
Liu, Jia-Ming
Liu, Zhi-Li
author_sort Chen, Wen-Zhao
collection PubMed
description The risk factors for predicting bone metastases in patients with breast cancer are still controversial. Here, a total of 2133 patients with breast cancer, including 327 with bone metastases (15.33%) and 1806 without bone metastases (84.67%) were retrospective reviewed from January 2005 to December 2015. The spine was found to be the most common site for bone metastases, followed by ribs (57.5%), pelvis (54.1%) and sternum (44.3%). The results indicated that axillary lymph node metastases and the concentrations of CA125, CA153, ALP and hemoglobin were the independent risk factors for bone metastases in patients with breast cancer. The receiver operating characteristics (ROC) curves showed that combined axillary lymph node metastases, high CA153 and ALP, with low hemoglobin were the most accurate biomarkers for predicting bone metastases in breast cancer [area under the curve = 0.900], and the sensitivity and specificity for the prediction were 78.5% and 87.8%, respectively. Therefore, breast cancer patients with more axillary lymph node metastases, high serum concentrations of CA125, CA153, ALP and low level of hemoglobin were closely related to bone metastases. Combined axillary lymph node metastases, CA153, ALP with hemoglobin have the highest predictive accuracy for bone metastases in breast cancer.
format Online
Article
Text
id pubmed-5595860
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55958602017-09-14 Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer Chen, Wen-Zhao Shen, Jun-Feng Zhou, Yang Chen, Xuan-Yin Liu, Jia-Ming Liu, Zhi-Li Sci Rep Article The risk factors for predicting bone metastases in patients with breast cancer are still controversial. Here, a total of 2133 patients with breast cancer, including 327 with bone metastases (15.33%) and 1806 without bone metastases (84.67%) were retrospective reviewed from January 2005 to December 2015. The spine was found to be the most common site for bone metastases, followed by ribs (57.5%), pelvis (54.1%) and sternum (44.3%). The results indicated that axillary lymph node metastases and the concentrations of CA125, CA153, ALP and hemoglobin were the independent risk factors for bone metastases in patients with breast cancer. The receiver operating characteristics (ROC) curves showed that combined axillary lymph node metastases, high CA153 and ALP, with low hemoglobin were the most accurate biomarkers for predicting bone metastases in breast cancer [area under the curve = 0.900], and the sensitivity and specificity for the prediction were 78.5% and 87.8%, respectively. Therefore, breast cancer patients with more axillary lymph node metastases, high serum concentrations of CA125, CA153, ALP and low level of hemoglobin were closely related to bone metastases. Combined axillary lymph node metastases, CA153, ALP with hemoglobin have the highest predictive accuracy for bone metastases in breast cancer. Nature Publishing Group UK 2017-09-12 /pmc/articles/PMC5595860/ /pubmed/28900285 http://dx.doi.org/10.1038/s41598-017-11700-4 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Chen, Wen-Zhao
Shen, Jun-Feng
Zhou, Yang
Chen, Xuan-Yin
Liu, Jia-Ming
Liu, Zhi-Li
Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer
title Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer
title_full Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer
title_fullStr Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer
title_full_unstemmed Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer
title_short Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer
title_sort clinical characteristics and risk factors for developing bone metastases in patients with breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595860/
https://www.ncbi.nlm.nih.gov/pubmed/28900285
http://dx.doi.org/10.1038/s41598-017-11700-4
work_keys_str_mv AT chenwenzhao clinicalcharacteristicsandriskfactorsfordevelopingbonemetastasesinpatientswithbreastcancer
AT shenjunfeng clinicalcharacteristicsandriskfactorsfordevelopingbonemetastasesinpatientswithbreastcancer
AT zhouyang clinicalcharacteristicsandriskfactorsfordevelopingbonemetastasesinpatientswithbreastcancer
AT chenxuanyin clinicalcharacteristicsandriskfactorsfordevelopingbonemetastasesinpatientswithbreastcancer
AT liujiaming clinicalcharacteristicsandriskfactorsfordevelopingbonemetastasesinpatientswithbreastcancer
AT liuzhili clinicalcharacteristicsandriskfactorsfordevelopingbonemetastasesinpatientswithbreastcancer